论文部分内容阅读
目的总结莫沙必利、乳果糖联合双歧杆菌治疗老年2型糖尿病功能性便秘患者的临床疗效,以更好的改善此类患者的生活质量。方法选择该院在2013—2015年期间收治治疗的老年2型糖尿病功能性便秘患者,总计80例作为实验研究对象。按照治疗方案不同分为采取莫沙必利、乳果糖治疗的参照组以及莫沙必利、乳果糖联合双歧杆菌治疗的实验组,对比两组患者的临床治疗效果以及两组患者临床用药不良反应发生几率。结果实验组患者的临床总有效率高于参照组,经统计学分析,组间差异有统计学意义(P<0.05)。对比两组患者临床用药不良反应发生几率,差异无意义(P>0.05)。结论莫沙必利、乳果糖联合双歧杆菌治疗老年2型糖尿病功能性便秘的临床疗效显著,能够更好地改善老年糖尿病患者的临床症状,且患者用药期间不会增加不良反应,建议临床治疗中推广应用。
Objective To summarize the clinical efficacy of mosapride, lactulose combined with bifidobacterium in the treatment of senile type 2 diabetic patients with functional constipation in order to better improve the quality of life of these patients. Methods A total of 80 patients with type 2 diabetes mellitus with functional constipation who were treated in the hospital from 2013 to 2015 were selected as experimental subjects. In accordance with the different treatment options to take mosapride, lactulose treatment of the reference group and mosapride, lactulose combined with bifidobacterium experimental group compared the clinical efficacy of two groups of patients and clinical treatment of two groups of patients with poor The probability of reaction. Results The total clinical effective rate of the experimental group was higher than that of the reference group. The statistical analysis showed that there was significant difference between the two groups (P <0.05). There was no significant difference between the two groups in the incidence of clinical adverse reactions (P> 0.05). Conclusion Mosapride, lactulose combined with bifidobacteria treatment of elderly patients with functional constipation type 2 diabetes significant clinical effect, can better improve the clinical symptoms of elderly patients with diabetes, and medication will not increase the adverse reactions, the proposed clinical treatment In the promotion and application.